Naluzotan

Naluzotan is a serotonin receptor antagonist that was initially developed by Pfizer for the treatment of anxiety and depression. However, it was discontinued in Phase II clinical trials due to lack of efficacy.

History

Naluzotan was first synthesized by Pfizer in the late 1990s as part of a research program aimed at developing new treatments for anxiety and depression. The compound was selected for further development based on its potent and selective antagonism of the 5-HT1A receptor, a subtype of the serotonin receptor that is implicated in the regulation of mood and anxiety.

Pharmacology

Naluzotan acts as a potent and selective antagonist at the 5-HT1A receptor. This means that it binds to this receptor and prevents it from being activated by serotonin or other agonists. This action is thought to increase the availability of serotonin in the brain, which can help to alleviate symptoms of anxiety and depression.

Clinical trials

Naluzotan entered Phase II clinical trials in the early 2000s. However, it failed to demonstrate sufficient efficacy in these trials and was subsequently discontinued. The reasons for this lack of efficacy are not fully understood, but may relate to the complex role of the 5-HT1A receptor in the regulation of mood and anxiety.

See also

• Serotonin receptor antagonist
• 5-HT1A receptor
• Pfizer

References

• 
  Naluzotan